Can You Prove It? The New Rules of Animal Nutrition, Biotics, and Regulatory Success (2026–2030)

Last week a founder asked me a question: "Can I add this ingredient to my product and still sell without any issue?" I answered him: "That is not the question anymore. It was the question ten years ago. Today the question is: can you prove it?"

In the US, and everywhere else I work, that one word is rewriting the future of animal nutrition. Feed additives, probiotics, postbiotics, pet products, microbiome technologies, all of it. For decades this industry mostly ran on a simple idea - if you could make it and someone would buy it, you were in business. Regulators, customers, investors, vets, pet parents... everyone sort of trusted the label. Those days are gone. Now everyone is asking the same thing from a different seat at the table. Is it safe? Is it compliant? Is there real evidence behind the claim? And I love it!

After helping commercialize more than 20 products across four continents in the last 15 years, I can say this with confidence: the companies that win between 2026 and 2030 will not be the ones with the flashiest ingredient. The ones who can stand in front of a regulator, a veterinarian, or an investor and say, "Here is the proof," without sweating will celebrate the win! The ground shifted under us and the map that founders were using is now out of date. A lot of people in this industry, however, are still reading the old map, and it doesn't match the territory. Two big things changed. If you missed them, you are working blind.

First one. The longtime agreement between FDA and AAFCO expired on October 1, 2024. For years, FDA provided scientific and technical support to AAFCO as new feed ingredient definitions were reviewed before appearing in the AAFCO Official Publication. That collaboration is over... So if your plan for a new ingredient still says "we'll go through the AAFCO definition process the old way," your plan needs a rewrite. What replaced it? FDA finalized Guidance for Industry #294, the Animal Food Ingredient Consultation process. People call it AFIC. It is an interim pathway that lets you consult directly with FDA's Center for Veterinary Medicine about a new ingredient and its safety, while FDA reviews its own Food Additive Petition and GRAS programs. On the other hand, AFIC is not the same as approval. It is a consultation process focused on safety review and regulatory transparency.

Here is the part you need to know - AFIC has a public-input piece. This means that FDA posts pending and completed consultations on its website with the substance, the intended use, the species, and the submitter. Interested parties get 90 days to weigh in (and yes, your competitors can see what you are working on, and they can comment as well). I suggest re-considering how you think about timing and confidentiality.

Second, AAFCO did not just walk away but launched their own review pathway, the Scientific Review of Ingredient Submissions (SRIS), run with the Kansas State University Olathe Innovation Campus. Instead of FDA CVM providing the scientific review support, SRIS now uses expert review panels to support the evaluation of new or modified AAFCO ingredient definitions. It is nongovernmental, and yes, it has a real cost attached.

So as of right now, you actually have four doors. FDA's GRAS route. The Food Additive Petition route. The interim AFIC consultation. And the AAFCO/K-State SRIS program. Picking the right one requires a smart strategy, expertise and a clear understanding of the products, species, claims, safety package, and market goals. Picking wrong can really be expensive!

Did you catch that? One of the biggest regulatory changes in animal feed ingredients in nearly two decades has already happened, and many founders and manufacturers are still describing the world as if it were 2022.

Why everyone suddenly needs science on biotics and regulatory

Here is what the daily problem looks like now. It is not a matter of "can we make this." Yes, we can make almost anything. But first, we need to answer a couple of questions! I know these questions keep the founders and investors up at night - but better to learn how to deal with it before it is too late. I've been asking these questions for over a decade to make sure the best possible products are coming to life/market, but now they turned out the required ones to be on the market. Here they are:

• Is the ingredient properly characterized?

• Do you have enough safety data?

• Are your efficacy claims actually supported, or just hopeful?

• Does the label comply?

• Could one marketing sentence quietly create a regulatory mess?

• And is the science strong enough to survive someone poking holes in it?

This is why regulatory strategy is not the last box you tick before launch. It is part of product development from day one and the teams that bolt it on at the end pay for it twice: once in money, once in lost time. This is also one of the reasons why I've developed "The Responsible Biotics Framework™." That framework is my way of connecting strain identity, safety, regulatory pathway, claims support, label language, and market access before a product is already too expensive to fix!

When I look at the big picture now, I see the demand stacking up in three places: Novel feed ingredients and biotics strategy. New probiotics, postbiotics, microbial metabolites, fermentation-derived ingredients, functional additives... they are entering the market faster than ever. But please! stop thinking that innovation without a regulatory plan would work! You need the right pathway, the safety documentation, real ingredient characterization, the technical dossier, the risk assessment, the submission (itself a whole process), and also a map for global market access. It may sound a lot but when it is done right, it feels like assembled itself. This is exactly the kind of work we build at Sigma BioVet Sciences.

Claims review and label compliance. Lots of good companies unfortunately tripped over their own feet on that for the last two years. I always say - your biggest risk is often not the product but the words you used to describe it. Gut health. Immune support. Microbiome modulation. Feed efficiency. Methane reduction. Animal well-being... Every one of those phrases has to pass a scientific test AND a regulatory test. The line between a compliant claim and a problem claim is sometimes three words. FDA keeps tightening the screws on truthful labeling, so a proactive label review is one of the cheapest forms of insurance you can buy.

Antibiotic alternatives and microbiome technologies. There is a stewardship pressure, it is real and speeding up. In February 2026, FDA finalized Guidance for Industry #273, defining durations of use for certain medically important antimicrobials fed to food-producing animals. It is voluntary but the direction of travel is obvious: use these drugs only when animals actually need them, for a defined window, no longer. FDA has identified approved applications/products, and the message is clear: undefined duration of use is no longer something that industry can ignore. So producers and animal health companies are looking hard at probiotics, postbiotics, synbiotics, competitive exclusion, and functional nutrition. Not as nice-to-haves anymore, but as real tools. And let me tell you before you ask, the future is not one magic solution. It is integrated strategies that support performance, health, sustainability, and responsible drug use all at once.

Where this is all heading: the five-year view

Here is a brief view which also shows that we all need to be ready for the new career definitions!

Methane-reducing feed additives. Sustainability stopped being a marketing bonus and became a business requirement, especially in dairy and beef. The science is moving fast. Here is the catch (even if it is not lovely): an environmental claim needs the same rigor as a health claim. You cannot simply wave your hands at "good for the planet" - you need defensible data.

Precision microbiome products. The era of generic probiotics is fading, and good riddance. "Contains beneficial bacteria" tells a vet almost nothing. I love the smart and deeper questions that I started to receive from veterinarians recently. They now know that strain is the whole story. And we all know that the future is strain-specific, even individualized, with a defined mode of action and a measurable outcome. I am truly glad that nobody is asking whether microbes matter - no longer! Now we are looking at which microbes, under which conditions, for which animal.

Postbiotics and microbial metabolites. One of my favorite frontiers and I am telling you - postbiotics will be the new star for the additives market! These non-living microbial products and metabolites bring real advantages... such as stability, manufacturing consistency, easier storage, sometimes a cleaner regulatory position. We are getting to a point where the metabolite a microbe produces can matter as much as the microbe itself.

Pet microbiome diagnostics. The companion animal world is leaning in. New platforms are starting to map microbial profiles tied to gut health, skin and ear issues, nutrition, and chronic disease. Yes, it looks 'still early', but this is going to become a real piece of personalized veterinary nutrition, and I am here for it.

Microbial characterization as a strategic must. As the expectations climb, knowing your organism cold is no longer a luxury, folks! Taxonomy, identity, genomic profile, safety attributes, functional properties. The companies that can generate and actually interpret that data will run circles around the ones who cannot.

So... The next winners in animal nutrition will not be defined by innovation alone. They will be defined by credibility.

Scientific credibility.

Regulatory credibility.

Data credibility.

We moved past "can we sell this ingredient." We are firmly in "can we prove it." For anyone building novel ingredients, microbiome technologies, biotics, or sustainable nutrition, the answer to that one question is going to decide your market access, your regulatory success, and how far you grow.

At Sigma BioVet Sciences I have never believed innovation and compliance are enemies. They are partners. The future belongs to the people who can turn good science into products the world actually trusts. I will leave you with the question I started with. Can you prove it? If you are not 100% sure, that uncertainty is exactly the conversation worth having before you spend another dollar on development.

With gratitude,

Dr. Nihan

Key Takeaways

• The FDA–AAFCO ingredient review agreement expired and the old "AAFCO definition" plan no longer exists the way it did.

• You now have four doors for a new ingredient: GRAS, Food Additive Petition, FDA's interim AFIC (GFI #294), and the AAFCO/K-State SRIS program. Choosing wrong is costly.

• AFIC is public. Competitors can see your pending ingredient and comment within 90 days, so plan timing and confidentiality up front.

• GFI #273 (Feb 2026) signals where antimicrobial stewardship is going. Biotics and functional nutrition are now real tools, not extras.

• Between 2026 and 2030, credibility beats novelty. Strain-level data, real characterization, and defensible claims decide market access.